نتایج جستجو برای: aminobenzyl purin

تعداد نتایج: 453  

Journal: :Acta poloniae pharmaceutica 2011
Vinata V Mulwad Bhushan P Langi Atul C Chaskar

6-Aminocoumarin on treatment with oxalyl chloride gives coumarinyl-6-isocynate (1a-c) which on treatment with glycine gives 1H-3-[2'-oxo-2'H-benzopyran-6'-yl]-5-imidazolidine-2, 4-dione (2a-c). (2a-c) when refluxed with o-chlorobenzaldehyde, m-hydroxybenzaldehyde, 3,4-dimethoxybenzaldehyde and 3-nitrobenzaldehyde separately gives 1H-5-(2"-chlorobenzylidene)-3-(2'-oxo-2'H-benzopyran-6'-yl) imida...

Journal: :The Journal of organic chemistry 2003
Maurizio Selva Pietro Tundo Alvise Perosa

In the presence of NaY faujasite, dimethyl carbonate (MeOCO(2)Me, DMC) is a highly chemoselective methylating agent of functionalized anilines such as aminophenols (1), aminobenzyl alcohols (2), aminobenzoic acids (3), and aminobenzamides (4). The reaction proceeds with the exclusive formation of N-methylanilines without any concurrent O-methylation or N-/O-methoxy carbonylation side processes....

Journal: :Nuclear medicine and biology 2003
Urs O Häfeli Junfeng Yu Farhad Farudi Yuhua Li Gilles Tapolsky

Magnetic targeted carriers (MTC) are magnetically susceptible microparticles that can be physically targeted to a specific site. MTC were radiolabeled with (111)In using three different methods. Reaction parameters were investigated in order to optimize the final properties of the labeled MTC. The reaction parameters studied were chelation agent, chelation time, temperature, radiolabeling time,...

Journal: :Drug development research 2004
Philip M Dunn Hak Sung Kim Kenneth A Jacobson Geoffrey Burnstock

Strategy, Management and Health PolicyEnabling Technology, Genomics, ProteomicsPreclinical ResearchPreclinical Development Toxicology, Formulation Drug Delivery, PharmacokineticsClinical Development Phases I-III Regulatory, Quality, ManufacturingPostmarketing Phase IVReplacement of the ribose moiety of adenosine 5'-triphosphate (ATP) with a carbocyclic ring constrained in either the Northern (N...

Journal: :The Journal of pharmacology and experimental therapeutics 2010
Maggie Ham Misa Mizumori Chikako Watanabe Joon-Ho Wang Takuya Inoue Takanari Nakano Paul H Guth Eli Engel Jonathan D Kaunitz Yasutada Akiba

Luminal ATP increases duodenal bicarbonate secretion (DBS) via brush border P2Y receptors. Because ATP is sequentially dephosphorylated to adenosine (ADO) and the brush border highly expresses adenosine deaminase (ADA), we hypothesized that luminal [ADO] regulators and sensors, including P1 receptors, ADA, and nucleoside transporters (NTs) regulate DBS. We measured DBS with pH and CO(2) electro...

2017
Christopher R. Coxon Christopher Wong Richard Bayliss Kathy Boxall Katherine H. Carr Andrew M. Fry Ian R. Hardcastle Christopher J. Matheson David R. Newell Mangaleswaran Sivaprakasam Huw Thomas David Turner Sharon Yeoh Lan Z. Wang Roger J. Griffin Bernard T. Golding Céline Cano

Nek2 (NIMA-related kinase 2) is a cell cycle-dependent serine/threonine protein kinase that regulates centrosome separation at the onset of mitosis. Overexpression of Nek2 is common in human cancers and suppression can restrict tumor cell growth and promote apoptosis. Nek2 inhibition with small molecules, therefore, offers the prospect of a new therapy for cancer. To achieve this goal, a better...

Journal: :The Journal of pharmacology and experimental therapeutics 1999
S Gunnarsdottir A A Elfarra

cis-3-(9H-Purin-6-ylthio)acrylic acid (PTA) is a structural analog of azathioprine, a prodrug of the antitumor and immunosuppressive drug 6-mercaptopurine (6-MP). In this study, we examined the in vitro and in vivo metabolism of PTA in rats. Two metabolites of PTA, 6-MP and the major metabolite, S-(9H-purin-6-yl)glutathione (PG), were formed in a time- and GSH-dependent manner in vitro. Formati...

Journal: :Molecular cancer therapeutics 2002
Franciscus M H de Groot Henk J Broxterman Hans P H M Adams Alexandra van Vliet Godefridus I Tesser Yvonne W Elderkamp Astrid J Schraa Robert Jan Kok Grietje Molema Herbert M Pinedo Hans W Scheeren

The design, synthesis, and initial biological evaluation of a doxorubicin prodrug that contains a dual tumor specific moiety, which allows enhanced tumor recognition potential, is reported. Both a tumor-specific recognition site and a tumor selective enzymatic activation sequence are incorporated in the prodrug. The first tumor-specific sequence is the bicyclic CDCRGDCFC (RGD-4C) peptide that s...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید